Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders
- 18 February 2026
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 208 (4) , 1369-1379
Abstract
Summary: In allogeneic haematopoietic stem cell transplantation (allo‐HSCT) for genetic disorders (GDs), predicting outcomes using the currently used myeloablative/reduced‐intensity conditioning classification is challenging. We examined the utility of the transplant conditioning intensity (TCI) score in allo‐HSCT for GDs. We retrospectively analysed 1077 patients who underwent first allo‐HSCT for GDs between 1987 and 2018. While no significant difference was observed in 3‐year non‐relapse mortality (NRM) between the myeloablative and reduced‐intensity conditioning group, 3‐year NRM in the TCI score ≥4.0 (TCI‐high) group (17.3%) was higher than that in the TCI score 0.5–3.5 (TCI‐low/intermediate) group (11.6%, p = 0.013). Multivariate analysis identified a high TCI score as a significant factor for NRM (HR 1.56, p = 0.011). Infection‐related mortalities were more prevalent in the TCI‐high group (7.9%) compared with the TCI‐low/intermediate group (3.2%). In contrast, patients in the TCI‐high group achieved a significantly higher rate of complete donor chimerism (71.7%) than those in the TCI‐low/intermediate group (62.2%, p = 0.022). TCI score is a valuable tool for predicting outcomes after allo‐HSCT for GDs as well as for guiding the selection of conditioning regimens tailored to the unique characteristics of GDs.Keywords
This publication has 30 references indexed in Scilit:
- Intensified conditioning regimens improved disease‐free survival and engraftment after unrelated single‐unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantationHematological Oncology, 2022
- Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency DiseasesJournal of Clinical Immunology, 2021
- High Graft-versus-Host Disease-Free, Relapse/Rejection-Free Survival and Similar Outcome of Related and Unrelated Allogeneic Stem Cell Transplantation for Aplastic Anemia: A Nationwide Swedish Cohort StudyTransplantation and Cellular Therapy, 2019
- Comparison of second transplantation and donor lymphocyte infusion for donor mixed chimerism after allogeneic stem cell transplantation for nonmalignant diseasesPediatric Blood & Cancer, 2016
- Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)International Journal of Hematology, 2015
- Long-Term Survival and Late Deaths after Hematopoietic Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of MetabolismTransplantation and Cellular Therapy, 2012
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Hematopoietic Stem Cell Transplantation for Bone Marrow Failure Syndromes in ChildrenTransplantation and Cellular Therapy, 2009
- Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2009
- Fludarabine-Based Reduced Intensity Conditioning for Stem Cell Transplantation of Fanconi Anemia Patients from Fully Matched Related and Unrelated DonorsTransplantation and Cellular Therapy, 2006